Aurinia Pharmaceuticals (TSE:AUP) Shares Down 3.5% – Here’s What Happened

by · The Cerbat Gem

Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) shares traded down 3.5% during mid-day trading on Monday . The company traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares were traded during trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.

Aurinia Pharmaceuticals Price Performance

The company has a market capitalization of C$2.15 billion and a PE ratio of -11.32. The company’s 50 day simple moving average is C$16.76. The company has a quick ratio of 11.02, a current ratio of 11.93 and a debt-to-equity ratio of 2.69.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

See Also